文献速递妇科

激素生物标志物在子宫内膜癌分子亚组中仍具预后相关性

Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2024-11-07

本研究为回顾性多中心队列研究,纳入739例子宫内膜癌患者,评估雌激素受体(ER)/孕激素受体(PR)表达在分子亚组中的预后价值。结果显示,在各分子亚组中ER/PR 90-100%表达者疾病特异性生存(DSS)最佳;PR 0-10%、p53mut、淋巴血管间隙浸润和FIGO III-IV期独立预后不良,PR 90-100%和POLEmut独立预后良好。

要点

  • 在各分子亚组中,ER/PR 90-100%表达患者的DSS最佳。
  • p53mut亚组中PR 90-100%表达的5年DSS为100.0%。
  • ER表达在MMRd和NSMP肿瘤中预后意义更明显,PR表达在p53mut和NSMP肿瘤中更明显。

核心结论

  • ER/PR表达在分子亚组内仍具预后相关性,三 tiered 截断值可细化预后评估。
  • 数据支持在临床实践中纳入ER/PR表达的常规评估。

研究设计与样本

  • 回顾性多中心队列研究,使用欧洲个体化治疗网络中心和加拿大温哥华的数据。
  • 共纳入739例患者,中位随访5.0年。
  • ER/PR免疫组化表达分组为:0-10%、20-80%、90-100%;分子亚组通过全面下一代测序或联合免疫组化确定为POLEmut、错配修复缺陷(MMRd)、p53mut和无特定分子谱(NSMP)。

主要发现

  • 肿瘤分类为POLEmut 9.1%(N=67)、MMRd 27.6%(N=204)、p53mut 20.8%(N=154)、NSMP 42.5%(N=314)。
  • 在所有分子亚组中,ER/PR 90-100%表达患者的DSS最佳。
  • p53mut亚组中,PR 90-100%表达的5年DSS为100.0%。
  • ER表达在MMRd和NSMP肿瘤中预后相关性更明显,PR表达在p53mut和NSMP肿瘤中更明显。
  • 在所有分子亚组中,PR 0-10%、p53mut、淋巴血管间隙浸润和FIGO III-IV期仍为DSS降低的独立预后因素;PR 90-100%和POLEmut仍为DSS改善的独立预后因素。

关键数值与推荐

  • ER/PR表达采用三级分组:0-10%、20-80%、90-100%。
  • 分子亚组包括POLEmut、MMRd、p53mut和NSMP。

临床怎么用

  • 作者认为数据支持在临床实践中纳入ER/PR表达的常规评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The prognostic relevance of hormonal biomarkers in endometrial cancer (EC) has been well-established. A refined three-tiered risk model for estrogen receptor (ER)/progesterone receptor (PR) expression was shown to improve prognostication. This has not been evaluated in relation to the molecular subgroups. This study aimed to evaluate the ER/PR expression within the molecular subgroups in EC. METHODS: A retrospective multicenter cohort study was performed and data from the European Network for Individualized Treatment centers and Vancouver, Canada were used. ER/PR immunohistochemical expression was grouped as: ER/PR 0-10 %, 20-80 % or 90-100 %. Molecular subgroups were determined with full next-generation sequencing or combined with immunohistochemistry: POLEmut, mismatch repair deficient (MMRd), p53mut and no-specific molecular profile (NSMP). RESULTS: A total of 739 patients were included (median follow-up 5.0 years). Tumors were classified as POLEmut in 9.1 %(N = 67), MMRd in 27.6 %(N = 204), p53mut in 20.8 %(N = 154) and NSMP in 42.5 %(N = 314). Among all molecular subgroups, patients with ER/PR 90-100 % expression revealed the best disease-specific survival (DSS). Within p53mut, PR 90-100 % expression showed a 5-year DSS of 100.0 %. ER expression is prognostic more relevant in MMRd and NSMP tumors while PR expression in p53mut and NSMP tumors. Across all molecular subgroups, PR 0-10 %, p53mut, lympho-vascular space invasion and FIGO stage III-IV remained independently prognostic for reduced DSS Whereas PR 90-100 % and POLEmut remained independently prognostic for improved DSS. CONCLUSION: We demonstrated that ER/PR expression remain prognostically relevant within the molecular subgroups, and that a three-tiered cutoff refines prognostication. These data support incorporating routine evaluation of ER/PR expression in clinical practice.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Vrede SW, Van Weelden WJ, Bulten J, et al. Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer. Gynecol Oncol. 2024. PMID: 39515079. doi:10.1016/j.ygyno.2024.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。